Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 1, 2010, Pages 203-207

  Pölcher, Martin ^a   Eckhardt, Meike ^a,b   Coch, Christoph ^b   Wolfgarten, Matthias ^a   Kübler, Kirsten ^a   Hartmann, Gunther ^b   Kuhn, Walther ^a   Rudlowski, Christian ^a  

^a Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Carboplatin; Neoadjuvant chemotherapy; Ovarian cancer; Paclitaxel; Sorafenib

Indexed keywords

CARBOPLATIN; PACLITAXEL; SORAFENIB; TOPOTECAN; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES FLUID; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SINGLE DRUG DOSE; SKIN TOXICITY; ADJUVANT THERAPY; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARBOPLATIN; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PYRIDINES;

EID: 77951917301     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1276-2     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106-130
2. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519-2529
3. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U (2006) Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S161-S192
4. Vergote IB, Tropé CG, Amant F, Kristensen GB, Sardi JE (2008) EORTC-GCG/NCIC-CTG randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA). In: 12th biennial meeting, International Gynecological Cancer Society (IGCS), Bangkok
5. Pölcher M, Mahner S, Ortmann O, Hilfrich J, Diedrich K, Breitbach GP, Hoss C, Leutner C, Braun M, Mobus V, Karbe I, Stimmler P, Rudlowski C, Schwarz J, Kuhn W (2009) Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer-a prospective multicenter phase II trial (PRIMOVAR). Oncol Rep 22:605-613
6. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
7. Thompson N, Lyons J (2005) Recent progress in targeting the Raf /MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5:350-356
8. Caraglia M, Tassone P, Marra M, Budillon A, Venuta S, Tagliaferri P (2006) Targeting Raf-kinase: molecular rationales and translational issues. Ann Oncol 17(7):vii124-vii127
9. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312-3318
10. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
11. Gianpaolo-Ostravage C, Carter C, Hibner B (2001) Anti-tumour efficacy of the orally active raf kinase inhibitor BAY 43-9006 in human tumour xenograft models. Proc Am Assoc Cancer Res 42:923
12. Welch S, Hirte H, Schilder RJ, Elit L, Townsley C, Tinker L, Pond G, Afinec A, Wright JJ, Oza M (2006) Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: a PMH phase II consortium trial. J Clin Oncol 24 (18 Suppl):276S
13. Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, Voliotis D, Christensen O, Brueckner A, Schwartz B (2006) Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 42:548-556
14. Dixon DO, Simon R (1988) Sample size considerations for studies comparing survival curves using historical controls. J Clin Epidemiol 41:1209-1213
15. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972
16. Takimoto CH, Awada A (2008) Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 61:535-548
17. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27:2823-2830
18. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, Voest EE, Benezra R, Kerbel RS (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14:263-273
19. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231
20. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239